semaglutide alzheimer clinical trial Semaglutide, exenatide, and their relatives are transforming diabetes and obesity care. Because their target also sits on brain cells, research into whether they slow Alzheimer's and Parkinson's has exploded: from 2 papers Novo Nordisk shares slide after

It shows we are still a thinking population

The EHR cohort was younger and had a larger proportion of men than the survey cohort (median age 44 years versus 52 years, and 37% male versus 18%), and both of these factors may contribute to some of the apparent difference in weight loss efficacy between self-report and EHR data

These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements

Ozempic and a host of similar GLP-1 drugs have officially entered the zeitgeist